LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%
efficacy for prevention of cervical cancer and precancerous lesions
associated with the human papillomavirus (HPV) types targeted by
the vaccine, conclude authors of an Article published early Online
and in the upcoming issue of The Lancet.
HPV types 16 and 18 account for 70% or more
cases of cervical cancer worldwide, but there are up to 15
oncogenic HPV types which can contribute to cervical cancer.
Professor Jorma Paavonen, Department of
Obstetrics and Gynaecology, University of Helsinki, Finland, and
colleagues randomly assigned 9 258 women to receive the HPV 16/18
vaccine, and 9 267 women in a control group received Hepatitis A
vaccine. Women who may have already been infected with HPV were
included in the study, as were women who had low-grade cytological
abnormalities at study entry.
With an average follow-up of 15 months, the
investigators found the vaccine had 90·4% efficacy against
high-grade cervical intraepithelial neoplasia (CIN 2/3, a cervical
cancer precursor) associated with HPV types 16 and 18. They found
also that many CIN lesions contained several oncogenic HPV types.
The level of protection against persistent infections with HPV16/18
at 6 and 12 months was 80·4% and 75·9%, respectively.
The study extended earlier results of cross-protection against HPV
45 and HPV 31, which cause up to 10% of cases of cervical
cancer.
The authors say: "Our results show that the
vaccine is effective, well-tolerated and immunogenic in a broad
population of young adult women, lending support to its potential
value in preventing CIN and cervical cancer."
In an accompanying Comment, Dr Jessica Kahn,
Cincinnati Children’s Medical Center, University of
Cincinnati College of Medicine, USA, and Dr Robert Burk, Albert
Einstein College of Medicine, New York, USA, state: "Althou
'"/>
Page: 1 2 Related medicine technology :1.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine2.
DOR BioPharma Announces Issuance of European Patent for Its Oral
Multivalent Botulinum Toxin Vaccine BT-VACC3.
From Clinical Cancer Research: Rethinking Therapeutic Cancer
Vaccine Trials4.
DOR BioPharma Announces Publication Describing Results of Its
Multivalent Botulinum Toxin Vaccine BT-VACC5.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types6.
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma7.
HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove
Superior at International Conference8.
New Flu Vaccine from PepTcell Could Provide Immunity Against All
Strains of Influenza Virus9.
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure
Reduction During Important Early Morning Period When Most Adverse
Cardiovascular Events Occur10.
New Flu Vaccine From PepTcell Could Provide Immunity Against All
Strains of Influenza Virus11.
Mymetics HIV Vaccine Demonstrates First-Ever Production of
Neutralizing IgA Antibodies in Non-Human Primate Model